Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,25
KB-0,19
PKN87,587,54-0,79
Msft506,76506,820,75
Nokia4,1014,232-4,06
IBM282,42282,57-0,43
Mercedes-Benz Group AG52,6752,681,49
PFE24,7724,78-2,27
15.07.2025 18:03:46
Indexy online
AD Index online
select
AD Index online
 

  • 24.06.2025 15:31:56
Biocryst Pharm (BCRX.F, Frankfurt)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
8,55 2,74 0,20 9 379
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 15.07.2025
Popis společnosti
Obecné informace
Název společnostiBioCryst Pharmaceuticals Inc
TickerBCRX
Kmenové akcie:Ordinary Shares
RICBCRX.O
ISINUS09058V1035
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.03.2025
Počet zaměstnanců k 31.12.2024 580
Akcie v oběhu k 30.04.2025 209 250 274
MěnaUSD
Kontaktní informace
Ulice4505 Emperor Blvd Ste 200
MěstoDURHAM
PSČ27703-8457
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon19 198 591 302
Fax19198591314

Business Summary: BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
Financial Summary: BRIEF: For the three months ended 31 March 2025, BioCryst Pharmaceuticals Inc revenues increased 57% to $145.5M. Net income totaled $32K vs. loss of $35.4M. Revenues reflect Product sales increase of 61% to $143.8M. Net Income reflects Research and development decrease of 20% to $37.3M (expense), Interest expense decrease of 4% to $23.5M (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSPharmaceutical Preparation Manufacturing
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICS2007Biological Product (exc Diagnostic) Mfg
NAICS2007Pharmaceutical Preparation Mfg
NAICS2007Research and Development in Biotechnology
NAICS1997Biological Product (except Diagnostic) Manufacturing
NAICS1997Pharmaceutical Preparation Manufacturing
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
SICBiological Prod's Not Diagnostic
SICBiological Prod's Not Diagnostic
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 15.07.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorJon Stonehouse6407.07.202505.01.2007
Chief Financial Officer, Head of Corporate DevelopmentBabar Ghias-07.07.202507.07.2025
Chief Commercial OfficerCharles Gayer5415.01.202015.01.2020
Chief Research & Development OfficerHelen Thackray5622.03.202122.03.2021
Chief Legal Officer, Corporate SecretaryAlane Barnes5901.01.2013